前立腺癌の遺伝子組み換えマウスモデルからの腫瘍オルガノイドの生成

Executive Industry Relevance

Genetically engineered mouse models of prostate cancer provide a physiologically relevant system for studying tumorigenesis and therapeutic response. Combining these models with 3D tumor organoid culture enables in vitro systems that recapitulate tumor architecture and support drug screening. This approach improves predictive confidence in preclinical oncology research by bridging genetic models with functional assays.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of tumor suppressor loss in prostate cancer using Cre-loxP models to validate genetic targets.
• Operational Value: Provides a reproducible method to isolate tumor tissue from GEMMs for downstream organoid generation.

Screening & Assay Development

• Scientific Value: Generates tumor organoids that maintain GFP expression from Cre-recombined tumor cells, enabling lineage tracking in drug response assays.
• Operational Value: Establishes a standardized 3D culture protocol using matrix domes and prostate organoid medium with R1881 and ROCK inhibitor for consistent tumor model propagation.

Translational & Preclinical Research

• Scientific Value: Supports comparison of tumor and normal epithelial organoids via dual Tomato/GFP expression to assess tumor-specific phenotypes.
• Operational Value: Facilitates metastatic lesion detection in lymph nodes and organs during necropsy, informing preclinical models of cancer progression.

Pipeline & Workflow Integration

The method integrates genetic model dissection with 3D culture to support discovery biology, assay development, and translational validation in prostate cancer research.

• Discovery Biology: Enables functional validation of tumor suppressor pathways through Cre-dependent recombination in prostate-specific GEMMs.
• Screening: Produces organoid cultures suitable for drug screening applications after solidification and medium addition.
• Analytics: Allows fluorescence-based tracking of Cre activity (GFP) and recombination history (Tomato) to distinguish tumor-derived from normal epithelial organoids.
• Translational Research: Supports continuity from autochthonous tumor models to ex vivo drug testing via organoid platforms that retain genetic lineage markers.
• Enterprise Reuse: Provides a reusable necropsy and organoid generation workflow applicable across multiple GEMMs and cancer types.

Operational & Enterprise Impact

• Scientific Value: Enhances target validation by linking genetic models to functional 3D phenotypes that reflect in vivo tumor behavior.
• Operational Value: Standardizes tumor tissue processing and organoid formation to improve reproducibility across laboratories.
• Strategic Value: Reduces reliance on 2D cell lines by providing genetically defined, microenvironment-informed models for preclinical testing.
• Portfolio Impact: Enables risk-adjusted prioritization of therapeutic candidates using organoid models that retain tumor-specific genetic signatures.

Implementation Considerations

• Requires expertise in mouse necropsy, prostate dissection, and fluorescence tissue identification.
• Dependent on dissection microscopy, centrifuges, pipettes, and temperature-controlled water baths for tissue processing.
• Necessitates standardized organoid medium supplemented with androgen R1881 and Y-27632 ROCK inhibitor for consistent culture.
• Requires adaptation of digestion and trituration steps based on tumor tissue consistency from different GEMMs.
• Limited by the need for fresh tissue processing post-necropsy to maintain organoid viability and genetic fidelity.

Biopharma FAQs